Shanghai Sigma-Audley New Material Technology: difference between revisions
Diff·revision 14 → 15·12:04, 17 Apr 2025
Difference between revision 14 and revision 15 of Shanghai Sigma-Audley New Material Technology. 4 lines changed; the page grew by 770 bytes.
| Revision 14 — 00:28, 30 Mar 2025 ForgeryFinder (talk) sentence case in headings per PP:MOS 7,523 bytes ±0 | Revision 15 — 12:04, 17 Apr 2025 BatchNumberBede (talk) add the note that self-published material is usable only for what it states about itself 8,293 bytes +770 | ||
|---|---|---|---|
| 19 | }} | 19 | }} |
| 20 | {{hatnote|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}} | 20 | {{hatnote|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}} |
| + | 21 | {{primarysources|date=July 2026|talk=Notability and the registered business scope}} | |
| 21 | 22 | ||
| 22 | '''Shanghai Sigma-Audley New Material Technology Co., Ltd.''' (trading as '''SSA'''; shanghaisigmaaudley.com) is a research-compound supplier trading as SSA from Shanghai, China, incorporated in 2018 under a registered name in the new-materials sector, and distributing research peptides and related materials with batch documentation.{{r|registry,selfpub}} | 23 | '''Shanghai Sigma-Audley New Material Technology Co., Ltd.''' (trading as '''SSA'''; shanghaisigmaaudley.com) is a research-compound supplier trading as SSA from Shanghai, China, incorporated in 2018 under a registered name in the new-materials sector, and distributing research peptides and related materials with batch documentation.{{r|registry,selfpub}} |
| ⋮ | ⋮ | ||
| 52 | Submitted reports on SSA material to July 2026 are concentrated on tirzepatide and semaglutide, with a smaller set on repair peptides. Reported [[Area percent purity|area percent]] figures have clustered in the high nineties, and where a certificate accompanied the sample the two figures have generally been close.{{r|reports}} | 53 | Submitted reports on SSA material to July 2026 are concentrated on tirzepatide and semaglutide, with a smaller set on repair peptides. Reported [[Area percent purity|area percent]] figures have clustered in the high nineties, and where a certificate accompanied the sample the two figures have generally been close.{{r|reports}} |
| 53 | 54 | ||
| + | 55 | The same limitation applies as everywhere in this sector: these are purchaser-submitted reports on purchaser-selected samples, so they describe the vials tested rather than the output those vials came from.{{r|reports}} The [[Peptide content|peptide content]] and water determinations that convert a reported purity into a mass are issued against a named lot on request, and a purchaser who wants the arithmetic to close should ask for both at the point of order rather than after dispatch.{{r|usp1503}} | |
| + | 56 | ||
| 54 | == References == | 57 | == References == |
| 55 | {{reflist}} | 58 | {{reflist}} |
| ⋮ | ⋮ | ||
| 58 | <ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref> | 61 | <ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref> |
| 59 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> | 62 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> |
| + | 63 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | |
| 60 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 64 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| 61 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> | 65 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> |